首页> 外文期刊>Molecular Biology >Mutation Frequencies in RNAi Targets in HIV-1 Genomes Obtained from Blood Plasma of Patients Receiving Anti-Retroviral Therapy
【24h】

Mutation Frequencies in RNAi Targets in HIV-1 Genomes Obtained from Blood Plasma of Patients Receiving Anti-Retroviral Therapy

机译:从接受抗逆转录病毒治疗的患者血浆中获得的RNAi靶标中的突变频率

获取原文
获取原文并翻译 | 示例
           

摘要

Gene therapy for AIDS based on RNA interference (RNAi) is currently looked upon as a promising alternative to conventional antiretroviral chemotherapy. The high variability of HIV-1 is the main challenge in developing new approaches to AIDS therapy. To date, about 18 million HIV-1 infected individuals receive antiretroviral therapy worldwide. As of 2017, about 44% of individuals with AIDS received antiretroviral therapy in Russia. Since the RNAs used for efficient RNAi and the corresponding targets in the viral transcript should be perfectly complementary to each other, it is necessary to continuously monitor the nucleotide sequences of clinical HIV-1 isolates obtained from blood and cells of na?ve patients and patients receiving antiretroviral therapy. Comprehensive analysis of the mutation frequencies in the viral genome is only possible with deep sequencing approaches. The present paper reports on an analysis of the mutation frequencies in six 100 bp genome regions in clinical HIV-1 isolates obtained from blood plasma of four Russian AIDS patients who have been receiving antiretroviral therapy for several years. These regions contain efficient RNAi targets. The average frequencies of all possible transversions and transitions within the RNAi targets and in their proximity have been estimated. It has been demonstrated that reverse transcriptase inhibition decreases the frequency of a number of reverse mutations. It has been found that mutations in RNAi targets are rarer (5–75 times lower than the mutation frequency for different nucleotide substitutions) than in the adjacent sequences. Our findings speak in favor of these conservative targets for developing new approaches to gene therapy of AIDS.
机译:基于RNA干扰(RNAi)的艾滋病基因疗法目前被视为常规抗逆转录病毒化疗的有希望的替代品。 HIV-1的高变异性是开发新方法辅助治疗方法的主要挑战。迄今为止,大约1800万HIV-1受感染的个体在全世界接受抗逆转录病毒治疗。截至2017年,约有44%的艾滋病患者在俄罗斯接受了抗逆转录病毒治疗。由于用于高效RNAi和病毒转录物中的相应靶标的RNA应该彼此完全互补,因此必须连续监测从NA'VE患者和患者的血液和细胞获得的临床HIV-1分离物的核苷酸序列接受抗逆转录病毒疗法。仅通过深度测序方法综合分析病毒基因组中的突变频率。本文报道了六种100bp基因组区域的突变频率在临床HIV-1分离株中的突变频率分析,从四个俄罗斯艾滋病患者获得了几年的血浆中获得的血浆。这些区域包含有效的RNAi目标。估计了RNAi目标中所有可能的横向和转换的平均频率并估计。已经证明,逆转录酶抑制降低了许多反向突变的频率。已经发现,RNAi靶中的突变比在相邻序列中的偏差(比不同核苷酸取代的突变频率低5-75倍)。我们的调查结果讲述了这些保守的目标,用于开发艾滋病基因治疗的新方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号